Abstract
Introduction

Non-receptor protein tyrosine kinase Fes, distinct from c-Src, c-Abl and other non-receptor protein tyrosine kinases
, is exclusively expressed in hematopoietic and vascular endothelial cells [3] . Fes is activated by oligomerization and subsequent autophosphorylation [4, 5] 
. Expression of kinase-inactive Fes (KI-Fes) in cultured endothelial cells exerts dominant negative effect on endogenous
Fes [6] . [6, 7] , and tube formation or capillary-like morphogenesis (i.e. morphological differentiation) induced by stromal cellderived factor 1-␣ (SDF-1␣) and sonic hedgehog (Shh) [8, 9] [10] . These results suggest that Fes could be a potential target for antiangiogenic therapy designed to shutdown intracellular signals mediated by multiple pro-angiogenic factors simultaneously. [11, 12] . Their specific receptor tyrosine kinases are VEGF receptor (VEGFR)-1, -2 and -3 [13] . We have previously shown that a prototype VEGF, VEGF-A, activated Fes through VEGFR-2, but not through VEGFR-1, in porcine aortic endothelial cells [14] . 
Using stable cell lines expressing KI-Fes, we demonstrated previously the involvement of Fes in chemotaxis of murine brain capillary endothelial cells (IBE cells) induced by fibroblast growth factor-2 (FGF-2) and angiopoietin 2 (Ang 2)
. Ang2-, SDF-1␣-and Shh-induced activation of phosphoinositide-3-kinase (PI3-kinase) is dependent on c-Fes kinase activity, whereas FGF-2 activates Src within focal adhesions in a manner dependent on Fes activity
Vascular endothelial growth factor (VEGF) is a family of closely related polypeptides, comprising VEGF-A, -B, -C, -D and -E, and placental growth factor
Preparation of siRNA-treated HUVECs
HUVECs were transfected with siRNA using HiPerFect ® reagent as described previously [16] . 
Chemotaxis assay
Chemotaxis assay was performed as described previously [17] . 
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously [16] . 
Results
Downregulation of Fes protein attenuates VEGF-A-induced chemotaxis and capillary-like morphogenesis by HUVECs
We first examined whether VEGF-A activates endogenous Fes in HUVECs. As shown in Figure 1A , (Fig. 3) (Fig. 1 B) . [18] . Hence effect on VEGF-A-induced chemotaxis and capillarylike morphogenesis [14] . This might be due to the compensatory mechanisms underlying multiple pathways other than Fes, such as Src and VEGFR-2 [14] [21] and Cas binds to focal adhesion kinase [22] , which could be associated with PI3-kinase [23] . Therefore 
Downregulation of Fes affects VEGF-A-mediated activation of Akt
We first examined whether treatment with Fes siRNA attenuates VEGF-A-induced activation of VEGFR-2. As shown in Figure 4A, treatment with Fes siRNA did not decrease the autophosphorylation of VEGFR-2. We also examined VEGF-A-induced MAPK activation. In both control siRNA-and Fes siRNA-treated cells, VEGF-A treatment produced comparable activation of MAPK. Since Akt is an important downstream effecter of PI3-kinase, we then examined the effect of Fes downregulation on VEGF-A-induced activation of Akt and found that Akt activation was impaired in Fes siRNA-treated cells. This observation suggests that downregulation of Fes seems to affect VEGF-A-induced activation of PI3-kinase/Akt pathway.
Discussion
In the present study, we showed for the first time that downregulation of Fes in cultured endothelial cells attenuated VEGF-A-induced Akt activation with subsequent inhibition of chemotaxis and capillary-like morphogenesis. These findings suggest that downregulation of Fes protein may potentially inhibit VEGF-A-dependent tumour angiogenesis. Expression of Fes protein was downregulated by the treatment with Fes siRNA in HUVECs
VEGF-A-induced chemotaxis and capillary-like morphogenesis by negative control siRNA-treated HUVECs were significantly inhibited by the treatment with LY294002. However, LY294002-treatment failed to inhibit VEGF-A-induced chemotaxis and capillarylike morphogenesis by Fes siRNA-treated HUVECs. These results suggest that VEGF-A-induced chemotaxis and capillary-like morphogenesis is at least partly regulated through PI3-kinase and Fes may be involved in the activation of this kinase. Indeed, downregulation of Fes neither inhibited VEGF-A-promoted autophosphorylation of VEGFR-2 nor activation of MAPK, but attenuated Akt phosphorylation. Thus, Fes plays significant roles in VEGF-A-promoted activation of PI3-kinase/Akt pathway and subsequent particular cellular responses, such as chemotaxis and capillary-like morphogenesis (Fig. 5). Tumour angiogenesis is not solely regulated by VEGF-A. In a preclinical model, chronic inhibition of VEGF-A signaling altered the characteristics of tumour growth from VEGF-A-dependent angiogenesis to FGF-2-dependent angiogenesis
